ACALABRUTINIB
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Treatment of relapsed/refractory disease
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||
Manner of administration:Oral
Restriction
Indication: Mantle cell lymphoma
Treatment phase: Initial treatment
Restriction
Indication: Mantle cell lymphoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: First line drug treatment of this indication - as monotherapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: First line drug treatment of this indication - in combination with obinutuzumab
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 6 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Continuing treatment (treatment cycles 3 to 14 inclusive) of first-line therapy -
in combination with venetoclax
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Grandfather arrangements - Transitioning from non-PBS to PBS-subsidised supply in
first-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Initial treatment (treatment cycles 1 to 2 inclusive) in first-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 1 | DPMQ: $7,052.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| CALQUENCE | |||||